Filing Flows › Health Care › Vivos (RDGL)
Vivos (RDGL) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 12, 2026 · Vivos (RDGL) Q2 2026 earnings results →
Q2 2026 Revenue up 143% year over year to $36K
Vivos made $36K in Q2 2026 (+143% Y/Y). Operating margin n/m, net loss $830K. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 12, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $36K in Q2 2026, up 143% year over year and up 1% from the previous quarter.
Operating costs exceeded revenue by $655K, an operating margin of -1798.2%. Total costs grew 0% against revenue growth of 143%. The fastest-growing cost line was Other operating costs (+16%). The quarter ended with a net loss of $830K, narrower than the previous quarter's $1.2M loss.
Operating cash flow was −$740K. Non-cash charges added back $0K of depreciation. Working capital and other items added $90K. Capital expenditures of $95K exceeded it, leaving free cash flow of −$834K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 12, 2026 | $36K | +143% | n/m | −$830K | −$740K |
| Q1 2026 | 10-Q | May 14, 2026 | $36K | +35% | n/m | −$1.2M | −$430K |
| Q4 2025 | 10-K | Mar 31, 2026 | $25K | +396% | n/m | −$1.1M | −$540K |
| Q3 2025 | 10-Q | Nov 12, 2025 | $2K | -62% | n/m | −$507K | −$458K |
| Q2 2025 | 10-Q | Aug 13, 2025 | $15K | +11% | n/m | −$646K | −$605K |
| Q1 2025 | 10-Q | May 9, 2025 | $27K | +494% | n/m | −$835K | −$455K |
| Q4 2024 | 10-K | Mar 24, 2025 | $5K | — | n/m | −$1.0M | −$471K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Vivos
Vivos Inc. (the “Company,” “we,” “us,” “our”) is a radiation oncology medical device company engaged in the development of its yttrium-90 (“Y-90”) based precision radionuclide therapy devices. This includes RadioGel® Precision Radionuclide Therapy™ (Human Division) for treating solid tumors and positive surgical margins in humans and IsoPet® (Animal Division) for treating solid tumors in animals. The Company also sells PLGA-g-PEG polymers and PrecisionGel™, a hydrogel polymer platform for delivering active pharmaceutical ingredients and therapeutic agents. A prominent team of radiochemists, scientists, and engineers, collaborating with strategic partners, including national laboratories, universities, and private corporations, lead the Company’s development efforts.
In its own words, from its 10-K, filed Mar 31, 2026.
Vivos against its Surgical & Medical Instruments & Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +143% against the peers' median +5%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| RDGL Vivos | Q2 2026 | $36K | +143% | n/m |
| MDLN Medline | Q3 2026 | $7.9B | +10% | 6.4% |
| MMM 3M | Q3 2026 | $6.6B | +1% | 23.7% |
| SYK Stryker | Q3 2026 | $6.5B | +8% | 15.9% |
| BSX Boston Scientific | Q3 2026 | $5.1B | +1% | 16.1% |
| BDX Becton Dickinson | Q3 FY26 | $5.0B | +5% | 13.3% |
| BAX Baxter International | Q3 2026 | $3.0B | +5% | 7.6% |
| SOLV Solventum | Q3 2026 | $1.9B | -7% | 3.5% |
| RMD ResMed | Q1 FY27 | $1.4B | +6% | 32.0% |
Source: Vivos 10-Q on SEC EDGAR · CIK 1449349 · Surgical & Medical Instruments & Apparatus
More on RDGL
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results